Neil Dahiya

DGTR Releases Updated Interested Parties List for Anti-Dumping Probe on PTFE Imports from China and Russia

The Directorate General of Trade Remedies (DGTR), operating under the Ministry of Commerce & Industry, has announced a revised list of stakeholders engaged in the current anti-dumping examination related to the importation of polytetrafluoroethylene (PTFE) from China and Russia. Polytetrafluoroethylene,

DGTR Releases Updated Interested Parties List for Anti-Dumping Probe on PTFE Imports from China and Russia Read More »

Emcure Pharma’s SAKHI Diabetes Awareness Initiative Earns Spot in Asia Book of Records

Emcure Pharmaceuticals, a prominent player in the women’s healthcare sector, celebrated a remarkable achievement on World Diabetes Day by securing a place in the Asia Book of Records. The company orchestrated the largest virtual campaign focused on women’s diabetes awareness,

Emcure Pharma’s SAKHI Diabetes Awareness Initiative Earns Spot in Asia Book of Records Read More »

Alnylam Details Results from Early Phase 1 Trial of Nucresiran, Highlighting Prolonged TTR Reduction Post-Single Dose

**Alnylam Pharmaceuticals, Renowned RNAi Therapy Leader, Unveils Promising Phase 1 Outcomes for Nucresiran** Alnylam Pharmaceuticals, a front-runner in the field of RNA interference (RNAi) therapeutics, disclosed the latest findings from its phase 1 research on nucresiran (previously known as ALN-TTRsc04),

Alnylam Details Results from Early Phase 1 Trial of Nucresiran, Highlighting Prolonged TTR Reduction Post-Single Dose Read More »

WATCHMAN FLX Device Outperforms Oral Anticoagulants in Bleed Risk Reduction After Cardiac Ablation: OPTION Trial Results

Boston Scientific Corporation unveiled promising outcomes from the OPTION global clinical study involving the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, sharing three years of primary endpoint results. The study, which contrasted the device with initial oral anticoagulation (OAC)

WATCHMAN FLX Device Outperforms Oral Anticoagulants in Bleed Risk Reduction After Cardiac Ablation: OPTION Trial Results Read More »

BioCryst Introduces Orladeyo in Ireland for Regular Prevention of HAE Recurrent Attacks in Those Aged 12 and Up

BioCryst Pharmaceuticals, Inc., a leading biotech firm, revealed that Ireland’s Health Services Executive (HSE) has endorsed Orladeyo (berotralstat) for the regular prevention of repeated hereditary angioedema (HAE) attacks in suitable patients aged 12 and above. This endorsement enables Irish HAE

BioCryst Introduces Orladeyo in Ireland for Regular Prevention of HAE Recurrent Attacks in Those Aged 12 and Up Read More »